From Half-Life to Clinical Impact: Mastering Time-Critical Supply Chains

1. Aug 13, 2026

How Axcellant helped a diagnostic study overcome isotope supply, manufacturing, and logistics constraints

In radiopharmaceutical development, we often say that the timeline is only as strong as the supply chain supporting it. For a recent multicenter diagnostic study, We faced a classic industry bottleneck: a single-source isotope dependency, ongoing technology transfer, and a rigid clinical launch date that left no room for error.

In nuclear medicine, “study start-up” is a misnomer if it only focuses on regulatory approvals. Success is dictated by the unforgiving physics of isotope decay. When you are dealing with a short half-life product, the margin for delay is nonexistent. Every hour post-manufacturing reduces the dose’s viability, meaning that manufacturing release, Class 7-compliant transport, and patient imaging windows must be synchronized with surgical precision. This means that operational planning becomes inseparable from clinical execution.

The risk of the single source

When you are dealing with isotopes that have a short half-life, every hour that passes after manufacturing directly erodes the product’s viability. If the isotope is produced at a single global location, the logistics are inherently fragile. Every additional transport leg – every customs delay or flight cancellation – doesn’t just cost money; it risks a wasted dose and a missed patient imaging window.

The study was a planned multicenter diagnostic radiopharmaceutical trial supported by a single global isotope supplier. At the same time, technology transfer to additional manufacturing partners was still in progress.

Waiting for the full rollout of new manufacturing sites would have increased the risk of a long delay. However, starting a trial under these conditions is a significant operational exposure. If Axcellant had waited for the full rollout of our regional manufacturing partners, we would have face a massive delay. If we would started too early without a plan for long-distance distribution, we would be risking a tremendous product waste.

In practical terms, the study required multiple production locations. This was not simply a manufacturing preference. It was a clinical operations requirement. Regional production capacity was needed to bring manufacturing closer to trial sites, protect the dosing schedule, reduce transport burden, and improve reliability.

Short half-life changes everything: manufacturing, shipment timing, and patient scheduling must be strictly aligned from day one.

The “operational bridge” strategy

To protect the sponsor’s timeline, we moved away from a linear planning model and implemented system which we call an “operational bridge.” Instead of treating manufacturing expansion as a secondary, post-launch detail, we integrated it into the heart of the clinical execution.

We secured a controlled, expedited “emergency supply pathway” from the original global source. This allowed us to initiate the trial on time and dose the first patients while the broader production network was still being validated. In parallel, we didn’t just “monitor” the technology transfer at regional sites; we accelerated it as part of the core start-up plan. This ensured that as the trial’s geographic footprint grew, our manufacturing capacity moved closer to the patients, effectively shortening the “logistics leg” and reduced the risk of the entire study.

The reality of centralized oversight

What often fails in these complex trials is communication. If the manufacturing site, the logistics provider, and the clinical site operate in silos, the product will inevitably degrade before it reaches the patient.

At Axcellant, we manage this through a centralized model that connects supply planning directly to site scheduling. This is where operational discipline becomes a clinical requirement. We have to synchronize manufacturing releases with Class 7-compliant transport and specific patient enrollment windows in real time. If a patient’s schedule shifts but the dose is already in transit, that’s a loss. If the dose is ready but the site isn’t prepared, that’s a failure. In a short half-life environment, these are the daily operational realities we manage to prevent fragmented decision-making.

A Strategic Blueprint for sponsors

For any sponsor moving into diagnostic radiopharmaceuticals, the lesson is that CMC planning and clinical operations are inseparable. To ensure your trial stays on track, you must address these five pillars long before the first patient is screened:

• Geographic Mapping: align your manufacturing capacity with your patient clusters to minimize transport windows.
• Integrated Timelines: your CMO technology transfer must be a milestone in your clinical plan, not a separate workstream.
• Class 7 Readiness: logistics isn’t just about shipping; it’s about meeting strict Class 7 transport requirements and country-specific shipment protocols from day one.
• Centralized Command: use a single oversight model to connect enrollment, logistics, and issue escalation.
• Sustainability: ensure that your model is economically viable when scaled across multiple regions.

In my experience, the ability to connect these dots is what determines whether a trial launches on time or becomes a cautionary tale of logistics failure. 

At Axcellant, we see nuclear medicine as an area where operational discipline directly influences the success of development. The ability to connect regulatory, clinical, manufacturing, and logistics planning is often what determines whether a complex radiopharmaceutical trial starts on time – and stays on track.

About the author: